Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pediatric Vosevi study in chronic hepatitis C
2018-000480-87Phase 2Completed
- Sponsor
- Gilead Sciences
- Start
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sofosbuvir + velpatasvir + voxilaprevir in chronic hepatitis C (CHC), sponsored by Gilead Sciences. Primary endpoint: Steady-state pharmacokinetics assessed by AUCtau. Started Oct 2018; status: completed.
02
Drugs
sofosbuvir + velpatasvir + voxilaprevir
03
Conditions
chronic hepatitis C (CHC)
Beyond the preview
Go deeper on 2018-000480-87.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000480-87.